[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alliance Foundation Trials, LLC.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100604426","phase-2-adjuvant-chemotherapy-and-immunotherapy-for-completely-resected-small-cell-lung-cancer-100604426",false,"NCT07149363","Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body weight \\>30 kg.\n* Must have a life expectancy of at least 12 weeks.\n* Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.\n* Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.\n* Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.\n* No prior systemic therapies, for small cell lung cancer.\n* Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agents.\n* Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.\n* Prior treatment with durvalumab.\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Superficial bladder cancer without active disease after treatment.\n  * Low grade prostate cancer without indication for active treatment.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.\n* Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.\n* Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.","ALL","18 Years",{"count":18,"type":19},65,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).",[25],"Small Cell Lung Cancer (SCLC)","RECRUITING","2026-06-25",{"date":29,"type":30},"2026-06-26","ACTUAL",{"date":32,"type":30},"2026-02-12",{"date":34,"type":19},"2031-02",{"name":36,"class":37},"Alliance Foundation Trials, LLC.","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":20,"phases":48,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100590154","longitudinal-screening-for-financial-hardship-to-improve-outcomes-in-patients-with-advanced-cancer-100590154","NCT06963723","Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer","PROOF","Inclusion Criteria:\n\n1. Minimum age of 21\n2. Understands English and\u002For Spanish\n3. Has a diagnosis of advanced\u002Fmetastatic cancer\n4. Currently undergoing systemic therapy (enteral or parenteral) with non-curative intent\n5. Has been receiving treatment for at least 2 months\n6. Life expectancy of at least 6 months, in the opinion of the treating oncologist\n7. Cognitively able to give informed consent\n\nExclusion Criteria:\n\n1. Under the age of 21\n2. Does not understand English or Spanish\n3. Has cognitive deficits that would preclude understanding of consent form and\u002For questionnaires\n4. Undergoing treatment with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer, primary curative therapy for testis cancer or lymphoma)\n5. Not undergoing systemic therapy (enteral or parenteral) with non-curative intent\n6. Receiving treatment for fewer than 2 months\n7. Life expectancy is less than 6 months, in the opinion of the treating oncologist","21 Years",{"count":47,"type":19},1000,[49],"NA","The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced\u002Fmetastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (HRQoL), symptom burden, patient-reported cancer treatment adherence, and exploratory outcomes of overall survival, patient-reported economic burden, patient-reported support received, patient-reported financial coping strategies, and health insurance literacy.",[52,53],"Advanced Cancer","Metastatic Cancer",[55],"Financial Toxicity","2026-05-08",{"date":58,"type":30},"2026-05-12",{"date":60,"type":30},"2025-07-01",{"date":62,"type":19},"2029-04-01",{"name":36,"class":37},7,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":73,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},"100399832","phase-1-a-study-of-targeted-agents-for-patients-with-recurrent-or-persistent-endometrial-cancer-100399832","NCT04486352","A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","A Phase IB\u002FII Multi-Cohort Study of Targeted Agents and\u002For Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer","EndoMAP","Key Inclusion Criteria:\n\n* Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy. Prior hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit. Chemotherapy given in conjunction with radiotherapy as a radiosensitizer will be counted as a systemic therapeutic regimen.\n* Measurable disease per RECIST 1.1\n* Availability of a representative tumor specimen that is suitable for determination of biomarker status via central testing (F1CDx) OR If a patient has a prior F1CDx report from 1 September 2019 or later, those NGS results can be used to determine biomarker status as long as the tumor tissue used in the report was obtained within 5 years prior to prescreening and appropriate signed consent is obtained from the patient.\n* Life expectancy \\> 12 weeks\n* Recovery from effects of recent radiotherapy, surgery, or chemotherapy\n\nKey Exclusion Criteria:\n\n* Endometrial tumors with the following histologies: squamous carcinomas, sarcomas\n* Other invasive malignancies within the last 5 years, except for non-melanoma skin cancer with no evidence of disease within the past 5 years AND localized breast cancer with previous adjuvant chemotherapy treatment for breast cancer completed \\> 5 years ago\n* Synchronous primary invasive ovarian or cervical cancer\n* Have an active or history of autoimmune disease or immune deficiency\n* Have a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis based on a screening chest computed tomography (CT) scan\n* Active tuberculosis\n* Severe infections within 4 weeks\n* Have received therapeutic oral or IV antibiotic medication within 2 weeks, except prophylactic antibiotic medication\n* Have significant cardiovascular disease\n* Are administered treatment with a live attenuated vaccine within 4 weeks, or anticipation of need for such a vaccine during the course of the study\n* Have prior allogeneic bone marrow transplantation or solid organ transplant\n* History of treatment with systemic immunostimulatory agents (including but not limited to interferons, interleukin-2) within 4 weeks or 5 half-lives of the drug, whichever is longer, prior to initiation of study treatment\n* History of treatment with systemic immunosuppressive medications within 2 weeks except acute, low-dose, systemic immunosuppressant medications, corticosteroids for chronic obstructive pulmonary disease and asthma, or mineralocorticoids and low-dose corticosteroids for participants with orthostatic hypotension or adrenocortical insufficiency\n* Have a history or clinical evidence of any untreated CNS disease, seizures not controlled with standard medical therapy, or history of cerebrovascular accident (stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months\n\nAFT-50A Specific Exclusion Criteria:\n\n● Prior treatment with T-cell costimulating or immune checkpoint blockade therapies including, but not limited to, CD137 agonists, anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies\n\nNote: Additional study cohort specific inclusion and exclusion criteria may apply based on cohort assignment.","FEMALE",{"count":75,"type":19},148,[77,22],"PHASE1","This is a Phase IB\u002FII multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and\u002For persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.",[80],"Endometrial Cancer","2026-03-31",{"date":83,"type":30},"2026-04-01",{"date":85,"type":30},"2021-10-20",{"date":87,"type":19},"2027-10",{"name":36,"class":37},21,""]